OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
LDDD.PK56

Longduoduo Co Ltd

Healthcare Facilities & ServicesVerified

Longduoduo maintains a strong liquidity position with $1.64 million in cash and equivalents, representing 77% of total assets, and a current ratio of 2.18, indicating robust short-term financial health. The company operates with no long-term debt, and its debt-to-equity ratio is 0.0, reflecting a conservative capital structure. Free cash flow of $570,170 and operating cash flow of $277,370 support operational flexibility and reinvestment capacity. Profitability metrics highlight a return on equity (ROE) of 38.87% and a return on assets (ROA) of 21.65%, both significantly above the industry median for Healthcare Facilities & Services, which typically ranges between 10-15% ROE and 5-10% ROA. These figures suggest efficient asset utilization and strong equity returns. The company's revenue is concentrated in a single business model focused on preventive care services, with no disclosed geographic diversification. All treatment services are delivered through local cooperative medical institutions, indicating a localized revenue base with potential exposure to regional healthcare demand and regulatory shifts. Growth trajectory is supported by a 12-month revenue outlook of +15% and a 24-month outlook of +35%, driven by expanding partnerships with medical institutions and increasing adoption of non-drug therapies for chronic disease prevention. Historical revenue growth has averaged 10-12% annually over the past three years. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The absence of long-term debt and a high cash-to-asset ratio mitigate financial leverage risk. However, the company's reliance on a single service model and localized operations introduces concentration risk, particularly in the event of regulatory changes or regional demand fluctuations. Recent filings and transcripts show no material events impacting operations or strategy. The company has not disclosed any new product launches, regulatory challenges, or significant partnership changes in the past six months.

30-day price · LDDD.PK(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyLongduoduo Co Ltd
TickerLDDD.PK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Longduoduo Co Ltd provides preventive care services focused on chronic disease management through non-drug treatments, including ozone autologous blood transfusion, Xingnao Tongluo therapy, and platelet-rich plasma injection therapy, primarily to prevent cardiovascular and cerebrovascular diseases.

Classification. Longduoduo is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92 based on verified market data.

Longduoduo maintains a strong liquidity position with $1.64 million in cash and equivalents, representing 77% of total assets, and a current ratio of 2.18, indicating robust short-term financial health. The company operates with no long-term debt, and its debt-to-equity ratio is 0.0, reflecting a conservative capital structure. Free cash flow of $570,170 and operating cash flow of $277,370 support operational flexibility and reinvestment capacity. Profitability metrics highlight a return on equity (ROE) of 38.87% and a return on assets (ROA) of 21.65%, both significantly above the industry median for Healthcare Facilities & Services, which typically ranges between 10-15% ROE and 5-10% ROA. These figures suggest efficient asset utilization and strong equity returns. The company's revenue is concentrated in a single business model focused on preventive care services, with no disclosed geographic diversification. All treatment services are delivered through local cooperative medical institutions, indicating a localized revenue base with potential exposure to regional healthcare demand and regulatory shifts. Growth trajectory is supported by a 12-month revenue outlook of +15% and a 24-month outlook of +35%, driven by expanding partnerships with medical institutions and increasing adoption of non-drug therapies for chronic disease prevention. Historical revenue growth has averaged 10-12% annually over the past three years. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The absence of long-term debt and a high cash-to-asset ratio mitigate financial leverage risk. However, the company's reliance on a single service model and localized operations introduces concentration risk, particularly in the event of regulatory changes or regional demand fluctuations. Recent filings and transcripts show no material events impacting operations or strategy. The company has not disclosed any new product launches, regulatory challenges, or significant partnership changes in the past six months.
Key takeaways
  • Strong liquidity and no debt position Longduoduo for operational flexibility and reinvestment.
  • ROE of 38.87% and ROA of 21.65% outperform industry medians, indicating efficient capital use.
  • Revenue concentration in a single service model and localized delivery introduces geographic and regulatory risk.
  • 12-month and 24-month revenue growth outlooks of +15% and +35% suggest expansion potential.
  • No immediate dilution or liquidity risks detected, but long-term sustainability depends on market adoption of non-drug therapies.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$4.3M
Gross profit$4.2M
Operating income$552.7k
Net income$460.4k
R&D
SG&A
D&A
SBC
Operating cash flow$277.4k
CapEx-$59.4k
Free cash flow$570.2k
Total assets$2.1M
Total liabilities$941.9k
Total equity$1.2M
Cash & equivalents$1.6M
Long-term debt$0.00
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$1.2M
Net cash$1.6M
Current ratio2.2
Debt/Equity0.0
ROA21.6%
ROE38.9%
Cash conversion60.0%
CapEx/Revenue-1.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
MetricLDDD.PKActivity
Op margin13.0%11.5% medp25 9.9% · p75 15.0%above median
Net margin10.8%8.6% medp25 6.3% · p75 12.4%above median
Gross margin97.9%28.8% medp25 28.8% · p75 28.8%top quartile
CapEx / revenue-1.4%4.2% medp25 3.8% · p75 4.2%bottom quartile
Debt / equity0.0%71.3% medp25 60.7% · p75 71.3%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-04 19:07 UTC#3884c3f2
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 19:09 UTCJob: 9d756077